Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit

Neurocrine Biosciences NASDAQ: NBIX outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company’s efforts to diversify beyond its largest product, INGREZZA.

Gano said China has become both a competitive force and an increasingly important source of biotech innovation. He said the speed, quality and breadth of science in the region have improved over the past decade, particularly in validated biology. Neurocrine has brought in primarily earlier-stage Chinese assets in recent years, he said.

While China has not changed Neurocrine’s overall balance between internal research and development and business development, Gano said it has increased the importance of speed and selectivity. Companies must develop efficient plans that can reach the market early while demonstrating differentiation throughout development, he said. Neurocrine may also use the Chinese ecosystem to accelerate development through contract research arrangements or collaborations in which Chinese partners advance programs through early clinical stages.

Gano said Neurocrine has made artificial intelligence and machine learning a corporate priority and has deployed OpenAI and Anthropic’s Claude tools across the organization. He differentiated near-term productivity opportunities from longer-term expectations that AI could materially improve research-and-development success rates.

According to Gano, employees are using the tools to accelerate workflows, analyze large data sets, reduce repetitive tasks and improve access to information across teams. He cited applications in medicinal chemistry, chemical development, translational science, clinical development and clinical-trial execution.

The company plans to assess AI through measurable outcomes, including whether it can speed decisions, reduce costs, improve clinical-trial enrollment and allow Neurocrine to advance more science without proportionately increasing headcount. Gano said AI’s ability to improve probabilities of technical success remains an earlier-stage opportunity, especially because novel biology often lacks the data needed to generate reliable machine-learning outputs.

Gano identified Medicare drug-price negotiations as the policy issue most directly affecting Neurocrine. INGREZZA’s maximum fair price is scheduled to be implemented in 2029, while a competing product in the same two-pr...